Showing results 2300 to 2319 of 14621
< previous
next >
| Preview | Issue Date | Title | Author(s) |
| 2012 | C-IBS patients lack monocyte derived β-endorphin which results in disinhibition of colonic afferent mechanosensitivity | Hughes, P.; Nicholson, I.; Bird, D.; To, S.; Isaacs, N.; Grasby, D.; Persson, J.; Harrington, A.; Brierley, S.; Zola, H.; Andrews, J.; Blackshaw, L.; Krumbiegel, D.; Digestive Disease Week (2012 : San Diego, California) |
| 2002 | C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss | Heilbronn, L.; Clifton, P. |
| 2017 | C-Reactive Protein as a Marker of Inflammation in Acute Psychosis and Schizophrenia | Weickert, T.; Jacomb, I.; Stanton, C.; Vasudevan, R.; Powell, H.; Liu, D.; Galletly, C.; Lenroot, R.; O'Donnell, M.; Weickert, C.S.; 72nd Annual Scientific Convention and Meeting of the Society of Biological Psychiatry (SOBP 2017) (18 May 2017 - 20 May 2017 : San Diego, CA) |
| 2007 | C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome | Moran, L.; Noakes, M.; Clifton, P.; Wittert, G.; Belobrajdic, D.; Norman, R. |
| 2013 | C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy | Puri, R.; Nissen, S.; Libby, P.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2012 | C-reactive protein, fibrinogen, and cardiovascular disease prediction | Kaptoge, S.; Di Angelantonio, E.; Pennells, L.; Wood, A.; White, I.; Gao, P.; Walker, M.; Thompson, A.; Sarwar, N.; Caslake, M.; Butterworth, A.; Amouyel, P.; Assmann, G.; Bakker, S.; Barr, E.; Barrett-Connor, E.; Benjamin, E.; Björkelund, C.; Brenner, H.; Brunner, E.; et al. |
| 2015 | C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies | Fuss, A.; Hope, C.; Deayton, S.; Bennett, G.; Holdsworth, R.; Carroll, R.; Coates, P. |
| 2014 | Cable monitoring solution - predict with certainty | Singh, K.; IET International Conference on Developments in Power System Protection (DPSP) (31 Mar 2014 - 3 Apr 2014 : Copenhagen, Denmark) |
| 2014 | Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study | Smith, M.; Sweeney, C.; Corn, P.; Rathkopf, D.; Smith, D.; Hussain, M.; George, D.; Higano, C.; Harzstark, A.; Sartor, A.; Vogelzang, N.; Gordon, M.; De Bono, J.; Haas, N.; Logothetis, C.; Elfiky, A.; Scheffold, C.; Laird, A.; Schimmoller, F.; Basch, E.; et al. |
| 2013 | Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial | Smith, D.; Smith, M.; Sweeney, C.; Elfiky, A.; Logothetis, C.; Corn, P.; Vogelzang, N.; Small, E.; Harzstark, A.; Gordon, M.; Vaishampayan, U.; Haas, N.; Spira, A.; Lara, P.; Lin, C.; Srinivas, S.; Sella, A.; Schöffski, P.; Scheffold, C.; Weitzman, A.; et al. |
| 2015 | Cabozantinib inhibits abiraterone's upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activity | Wang, X.; Huang, Y.; Christie, A.; Bowden, M.; Lee, G.; Kantoff, P.; Sweeney, C. |
| 2008 | Cachexia and neuropeptide Y | Morley, J.; Farr, S. |
| 2013 | Cachexia as a major public health problem: frequent, costly and deadly | Farkas, J.; von Haehling, S.; Kalantar-Zadeh, K.; Morley, J.; Anker, S.; Lainscak, M. |
| 2008 | Cachexia: a new definition | Evans, W.; Morley, J.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; et al. |
| 2020 | Cadmium stress dictates central carbon flux and alters membrane composition in Streptococcus pneumoniae | Neville, S.L.; Eijkelkamp, B.A.; Lothian, A.; Paton, J.C.; Roberts, B.R.; Rosch, J.W.; McDevitt, C.A. |
| 2019 | Caesarean section and risk of type 1 diabetes: whole-of-population study | Begum, M.; Pilkington, R.; Chittleborough, C.; Lynch, J.; Penno, M.; Smithers, L. |
| 2019 | CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan | Vennin, C.; Mélénec, P.; Rouet, R.; Nobis, M.; Cazet, A.S.; Murphy, K.J.; Herrmann, D.; Reed, D.A.; Lucas, M.C.; Warren, S.C.; Elgundi, Z.; Pinese, M.; Kalna, G.; Roden, D.; Samuel, M.; Zaratzian, A.; Grey, S.T.; Da Silva, A.; Leung, W.; Johns, A.L.; et al. |
| 2018 | Caffeine for apnea of prematurity and brain development at 11 years of age | Kelly, C.E.; Ooi, W.L.; Yang, J.Y.M.; Chen, J.; Adamson, C.; Lee, K.J.; Cheong, J.L.Y.; Anderson, P.J.; Doyle, L.W.; Thompson, D.K. |
| 2016 | Caffeine toxicity in forensic practice: possible effects and under-appreciated sources | Musgrave, I.; Farrington, R.; Hoban, C.; Byard, R. |
| 2007 | Calcific myonecrosis: case report and radiopathological correlation | Constantine, S.; Brennan, C.; Sebben, R. |
